They are not intended to represent clinical evidence in humans, and BPC+TB Blend has not been approved by the FDA, EMA, or any other regulatory authority for any indication
Hill SM, Blask DE
R., Zamfir, M., Stancu, M
Injection methods can change how comfortable the process feels and how the body uses the nutrients
Additional targets include efflux pumps (e.g., Flu1, Mdr1, Cdr1, Cdr2), kinases and transcription factors (e.g., Snf1, Skr1), signaling proteins (e.g., Hog1, calcineurin), ribosomal proteins (e.g., S3, S6, L4), resistance regulators (e.g., Pdr1), and phosphodiesterases (e.g., Pde1, Pde2) (Day et al., 2018
Original and mutated sequences of eight MYB binding sites one by one were listed in Supplementary Table S6